Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
4D Pharma
Checkpoint_Therapeutics |
| gptkbp:CEO |
gptkb:Garo_H._Armen
|
| gptkbp:clinicalTrials |
peer review
data data collection ongoing protocols Phase 1 biomarkers completed ethical considerations informed consent regulatory approval safety statistical analysis suspended Phase 2 Phase 3 investigators randomization sponsors publication monitoring efficacy adverse events study design results patient consent blinding clinical trial registry terminated enrollment clinical endpoints dosing regimen multiple cancer therapies patient population results dissemination FDA_approved |
| gptkbp:focus |
immuno-oncology
|
| gptkbp:founded |
1994
|
| gptkbp:founder |
gptkb:Garo_H._Armen
|
| gptkbp:headquarters |
gptkb:Lexington,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Agenus Inc.
|
| gptkbp:investmentFocus |
institutional investors
retail investors |
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co. |
| gptkbp:products |
AgenT-Cell
AgenT-Cell-1 AgenT-Cell-10 AgenT-Cell-2 AgenT-Cell-3 AgenT-Cell-4 AgenT-Cell-5 AgenT-Cell-6 AgenT-Cell-7 AgenT-Cell-8 AgenT-Cell-9 |
| gptkbp:researchInterest |
academic institutions
research organizations |
| gptkbp:revenue |
$50 million (2020)
|
| gptkbp:stockSymbol |
AGEN
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.agenusbio.com
|